For UA/NSTEMI patients in whom an initial conservative (ie, noninvasive) strategy is selected, clopidogrel or ticagrelor (loading dose followed by daily maintenance dose) should be added to aspirin and anticoagulant therapy as soon as possible after admission and administered for up to 12 months.9,10,13 (Level of Evidence: B) modified (included ticagrelor and changed duration of therapy to up to 12 months ). 5. For UA/NSTEMI patients in whom an initial conservative strategy is selected, if recurrent symptoms/ischemia, heart failure, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed.55,72 (Level of Evidence: A) Either an IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban46,50,51 Level of Evidence: A ), clopidogrel (loading dose followed by daily maintenance dose13 Level of Evidence: B ), or ticagrelor (loading dose followed by daily maintenance dose9 Level of Evidence: B ) should be added to aspirin and anticoagulant therapy before diagnostic angiography (upstream). (Level of Evidence: C) modified (included ticagrelor). 6. A loading dose of P2Y12 receptor inhibitor therapy is recommended for UA/NSTEMI patients for whom PCI is planned. One of the following regimens should be used: modified (included ticagrelor and changed loading dose of clopidogrel and associated level of evidence to be concordant with 2011 PCI guideline75). a. Clopidogrel 600 mg should be given as early as possible before or at the time of PCI32,73,74 (Level of Evidence: B) or b. Prasugrel* 60 mg should be given promptly and no later than 1 hour after PCI once coronary anatomy is defined and a decision is made to proceed with PCI7 (Level of Evidence: B) or c. Ticagrelor 180 mg should be given as early as possible before or at the time of PCI.9 (Level of Evidence: B) 7. 